EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia

This article was originally published here

The approval for ZYNTEGLO is for the treatment of TDT in patients 12 years and older who do not have a β0/β0 genotype and for those who are

The post EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply